HOME >> MEDICINE >> NEWS
Promising West Nile virus vaccine protects monkeys

ed West Nile virus into all 20 monkeys. The 12 monkeys that received a version of the West Nile/dengue 4 virus developed high levels of neutralizing antibodies that successfully fought the West Nile virus.

Because it was less able to replicate, the West Nile/dengue 4 virus with the RNA deletion will be the first one used in the planned clinical trials in humans. Scientists favor this virus as a vaccine because it triggered high levels of West Nile antibodies and did not produce measurable levels of virus in monkeys. It could provide life-long immunity against West Nile virus and would be highly unlikely to mutate into a disease-causing virus. It is also not likely to be passed via mosquitoes to birds or other animals.


'"/>

Contact: Linda Joy
ljoy@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
18-Aug-2003


Page: 1 2 3

Related medicine news :

1. Promising new strategy for Swedish medical research
2. Promising treatments for Huntingtons disease identified in UCI study
3. Promising results for malaria vaccine trial
4. Promising diagnostic test for sleeping sickness
5. Promising new treatment options for people with co-existing alcohol-use and psychiatric disorders
6. Promising drug fails to thwart fatal lung disease in large trial
7. Promising drug proves ineffective as treatment for hearing loss
8. Promising new treatment preserves bone mass in mice; May help women and men with osteoporosis
9. Promising vaccine may provide long-lasting protection against malaria
10. Promising new research on schizophrenia causes
11. UI Study Suggests Promising Treatment For Diabetic Pregnancies

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Promising West Nile virus vaccine protects monkeys

(Date:5/20/2013)... The automated external defibrillator market is ... - semi-automated and fully automated defibrillators. Based on ... namely, hospitals, pre-hospital, public access, alternate care, and ... external defibrillators play an important role in saving ... the life-saving potential of AEDs, legislations requiring installation ...
(Date:5/20/2013)... May 20, 2013 Recent environmental ... of using green and sustainable inputs in packaging ... implemented regulations to promote the use of sustainable ... and Labelling Services industry . “Tax subsidies and ... says IBISWorld industry analyst Deonta Smith. “For example, ...
(Date:5/20/2013)... Florida (PRWEB) May 20, 2013 In order ... supplemental health and wellness team from DrSmartphoneMD launched an article ... serious sunburns. , The series launched with the ... that members of the DrSmartphoneMD program are not one of ... team explained that more than 90% of all skin cancer ...
(Date:5/20/2013)... 20, 2013 Parker Waichman LLP, a ... victims injured by defective drugs, has filed a lawsuit ... that use of the diabetes drug medication Actos ... on April 30, 2013, in the U.S. District Court ... where it is one of thousands of cases pending ...
(Date:5/20/2013)... May 20, 2013 Mirena IUD ... the multidistrict litigation recently established in U.S. District Court, ... According to court records, the litigation’s first Status ... appointments to Plaintiff’s leadership positions were discussed. So ... the Southern District of New York, all of which ...
Breaking Medicine News(10 mins):Health News:North America Leads Automated External Defibrillator Market (AED), Says New Research Report at ReportsnReports.com 2Health News:North America Leads Automated External Defibrillator Market (AED), Says New Research Report at ReportsnReports.com 3Health News:Packaging and Labelling Services in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Packaging and Labelling Services in Canada Industry Market Research Report Now Available from IBISWorld 3Health News:Combat Skin Cancer In Summer Months 2Health News:Taking Actos for Two Years Caused Bladder Cancer, Alleges Lawsuit Filed by Parker Waichman LLP on Behalf of South Dakota Man 2Health News:Mirena IUD Lawsuit News: Bernstein Liebhard LLP Reports on First Status Conference in Federal Mirena Litigation 2Health News:Mirena IUD Lawsuit News: Bernstein Liebhard LLP Reports on First Status Conference in Federal Mirena Litigation 3
(Date:5/20/2013)... VIEJO , Kalifornien, 20. Mai 2013 ... bekannt, dass das Unternehmen die CE-Kennzeichnung für ... zur Embolisation von Aneurysmen erhalten hat. Das ... Europa bereits mit der kontrollierten Einführung dieser ... bietet die SL-Produktfamilie auch ein verbessertes Handling, ...
(Date:5/20/2013)... , BERLIN and ... Arthroscopy Devices Market to 2018 ... Invasive Procedures to Drive Future Growth" looks at the ... six arthroscopy device market segments: arthroscopes, arthroscopy shavers, arthroscopy ... systems, and arthroscopy visualization systems. The report provides comprehensive ...
(Date:5/20/2013)... Md. , May 20, 2013  Neuralstem, Inc. ... Feldman , MD, PhD, principal investigator, presented updated ... stem cell (NSI-566) trial in the treatment of amyotrophic ... ,s disease) at the neuro diabetes special medical symposium ... In a talk called "Recent Therapeutic Advances in Stem ...
Breaking Medicine Technology:Sequent Medical, Inc. bringt neue SL-Produktfamilie seiner WEB Geräte zur Embolisation von Aneurysmen auf den Markt 2Sequent Medical, Inc. bringt neue SL-Produktfamilie seiner WEB Geräte zur Embolisation von Aneurysmen auf den Markt 3Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Arthroscopy Devices Market Growth 2Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Arthroscopy Devices Market Growth 3Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Arthroscopy Devices Market Growth 4Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 2Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 3Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 4
Cached News: